Previous Article | Next Article 
Journal of Virology, October 2000, p. 9353-9361, Vol. 74, No. 20
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Mutational Definition of Functional Domains within
the Rev Homolog Encoded by Human Endogenous Retrovirus K
Hal P.
Bogerd,
Heather L.
Wiegand,
Jin
Yang, and
Bryan R.
Cullen*
Howard Hughes Medical Institute and
Department of Genetics, Duke University Medical Center, Durham,
North Carolina 27710
Received 2 June 2000/Accepted 18 July 2000
 |
ABSTRACT |
Nuclear export of the incompletely spliced mRNAs encoded by several
complex retroviruses, including human immunodeficiency virus type 1 (HIV-1), is dependent on a virally encoded adapter protein, termed Rev
in HIV-1, that directly binds both to a cis-acting viral
RNA target site and to the cellular Crm1 export factor. Human
endogenous retrovirus K, a family of ancient endogenous retroviruses
that is not related to the exogenous retrovirus HIV-1, was recently
shown to also encode a Crm1-dependent nuclear RNA export factor, termed
K-Rev. Although HIV-1 Rev and K-Rev display little sequence identity,
they share the ability not only to bind to Crm1 and to RNA but also to
form homomultimers and shuttle between nucleus and cytoplasm. We have
used mutational analysis to identify sequences in the 105-amino-acid
K-Rev protein required for each of these distinct biological
activities. While mutations in K-Rev that inactivate any one of these
properties also blocked K-Rev-dependent nuclear RNA export, several
K-Rev mutants were comparable to wild type when assayed for any of
these individual activities yet nevertheless defective for RNA export.
Although several nonfunctional K-Rev mutants acted as dominant negative inhibitors of K-Rev-, but not HIV-1 Rev-, dependent RNA export, these
were not defined by their inability to bind to Crm1, as is seen with
HIV-1 Rev. In total, this analysis suggests a functional architecture
for K-Rev that is similar to, but distinct from, that described for
HIV-1 Rev and raises the possibility that viral RNA export mediated by
the ~25 million-year-old K-Rev protein may require an additional
cellular cofactor that is not required for HIV-1 Rev function.
 |
INTRODUCTION |
Retroviral replication requires the
coordinated expression of both unspliced and spliced forms of the
initial, genome-length viral transcript. However, cells have evolved
mechanisms to prevent the nuclear export of incompletely spliced
cellular mRNAs, i.e., pre-mRNAs, via the canonical cellular mRNA export
pathway. Because these same mechanisms can also lead to nuclear
retention of incompletely spliced retroviral mRNAs, these viruses have
had to evolve ways to target their incompletely spliced transcripts to
the cytoplasm via export pathways that are not normally used by
cellular mRNA molecules (reviewed by in references 8
and 34). One such mechanism, first identified in the
pathogenic lentivirus human immunodeficiency virus type 1 (HIV-1),
targets unspliced viral transcripts into a nuclear export pathway
normally used for small nuclear RNAs and certain proteins that shuttle
between nucleus and cytoplasm (10, 14, 29, 32, 42).
Specifically, HIV-1 encodes an adapter protein, termed Rev, that can
bind to, and multimerize on, a cis-acting viral RNA target
site termed the HIV-1 Rev response element (H-RRE) (28, 29,
44). In the nucleus, Rev also binds, via a leucine-rich nuclear
export signal (NES), to the cellular export factor Crm1 in an
interaction that is dependent on the presence of the GTP-bound form of
the cellular G-protein Ran (3, 11, 31, 38). Crm1 in turn
interacts with components of the nuclear pore and thereby targets the
resultant ribonucleoprotein complex to the cytoplasm (31).
Subsequently, other lentiviruses were also shown to encode Rev
proteins, while members of the distinct human T-cell leukemia virus
type 1 (HTLV-1) family of oncoretroviruses encode a Rev homolog, termed
Rex, that acts to induce the nuclear export of unspliced HTLV-1
transcripts by recruiting Crm1 to a cis-acting RNA target
site, the Rex response element (3, 16, 21).
Until recently, only these two retroviral subgroups had been shown to
encode a Rev-like nuclear RNA export activity. In contrast, other
exogenous retroviruses either directly recruit a cellular nuclear
export factor, distinct from Crm1, to an RNA target site termed a
constitutive transport element or induce nuclear export of their
incompletely spliced transcripts via an unknown mechanism (8,
34). Recently, however, a third type of Crm1-dependent retroviral RNA export factor, termed K-Rev, was identified in the
human endogenous retrovirus K (HERV-K) and shown to induce the nuclear
export of unspliced mRNAs bearing a copy of a HERV-K-derived RNA target
site, the K-RRE (27, 43). The HERV-K family of endogenous
retroviruses is present at between 50 and 100 copies per haploid human
genome and entered the human germ line over a ~25 million-year period
starting ~30 million years ago (1, 39). No exogenous
retrovirus closely related to the HERV-K family is known to exist
(17), and these endogenous viruses can therefore be viewed
as fossil remnants of an exogenous virus family that is now probably
extinct. However, the presence in the HERV-K genome of a nuclear RNA
export factor and a cis-acting RNA target site that together
are closely comparable in function to HIV-1 Rev (H-Rev) and the H-RRE
does suggest that this RNA export activity arose fairly early in
retroviral evolution (27, 43).
Previously, it has been demonstrated that the 116-amino-acid (aa) H-Rev
protein and the 105-aa K-Rev protein share several biological
properties, although they lack any evident sequence similarity
(27, 43). Both H-Rev and K-Rev can specifically bind to
their viral RNA response element, form homomultimers, and bind to Crm1
in a Ran · GTP-dependent manner (43). Curiously, although both H-Rev and K-Rev shuttle between nucleus and cytoplasm, H-Rev displays a predominantly nuclear and nucleolar localization at
steady state whereas K-Rev is largely cytoplasmic (3, 43). However, K-Rev does localize to nuclei and nucleoli when Crm1 function
is inhibited, thus demonstrating that the cytoplasmic localization of
K-Rev is dependent on ongoing, Crm1-dependent nuclear export (27,
43).
The H-Rev protein has been subjected to intense mutational analysis,
and the sequences involved in RNA binding, multimerization, and
Crm1-dependent nuclear export are now well defined (8, 34).
In contrast, no mutational analysis of K-Rev has been previously described. Here, we report the identification of sequences within K-Rev
that are critical for K-RRE and Crm1 binding, multimerization, and
nucleocytoplasmic shuttling and identify mutants of K-Rev that can
function as specific dominant negative inhibitors of wild-type K-Rev function.
 |
MATERIALS AND METHODS |
Construction of molecular clones.
The following mammalian
expression plasmids have been previously described: the indicator
plasmids pG6(
31)HIVLTR
TARCAT (37), pDM128/CMV
(23, 30), and pDM128/K-RRE (43); effector
plasmids pcRev (29), pSG424/Crm1, pSG424/K-Rev,
pBC12/CMV/K-Rev/VP16, pBC12/CMV/K-Rev (43), and
pBC12/CMV/
CAN (3); and control plasmids pBC12/CMV and
pBC12/CMV/
-gal (3). Derivatives of pBC12/CMV/K-Rev
encoding K-Rev mutants K1 through K14 were constructed by PCR
mutagenesis using primers that substituted a NotI site (i.e., 5'-GCG · GCC · GC-3') for the sequences underlying
the residues boxed in the K-Rev protein sequence shown in Fig.
1. This results in the substitution of
alanines for the indicated residues. After PCR amplification, the
resultant K-Rev DNA sequences were cleaved at flanking 5'
BspHI and 3' XhoI sites and inserted into
pBC12/CMV cleaved with NcoI and XhoI. Plasmids
encoding fusions of the VP16 activation domain to K-Rev mutants K1
through K14 were prepared as previously described (43) for
the wild-type pBC12/CMV/K-Rev/VP16 plasmid.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Predicted amino acid sequence of the K-Rev protein. The
14 introduced mutations resulted in the substitution of alanine for the
indicated residues.
|
|
Yeast K-Rev expression plasmids were generated by PCR amplification of
wild-type and mutant K-Rev genes (K1 through K14) using
primers that
introduced flanking
EcoRI sites. After cleavage with
EcoRI, the resultant DNA fragments were cloned in pPGK/VP16,
in
frame with the VP16 transcription activation domain and simian
virus
40 T-antigen nuclear localization signal (NLS) present in
pPGK/VP16
(
5). The wild-type K-Rev
EcoRI fragment was also
cloned into pGBT9 (Clontech Inc.), to generate pGBT9/K-Rev, which
encodes the GAL4 DNA binding domain fused to full-length K-Rev.
The
full-length K-RRE (HERV-K residues 8719 to 9152) was cloned
into the
RNA expression plasmid pMS2-2 (
36) in both orientations
to
generate pMS2/K-RRE/s and pMS2/K-RRE/as for use in yeast three-hybrid
assays.
Transfection of human cells.
For analysis of K-Rev function,
293T cells (35-mm-diameter plates) were transfected by the calcium
phosphate method using 25 ng of the pDM128/K-RRE reporter plasmid, 25 ng of the pBC12/CMV/
-gal internal control, 50 ng of a
pBC12/CMV/K-Rev effector plasmid (wild type or mutant) or pBC12/CMV as
a negative control, and 1,000 ng of pBC12/CMV. To assay for dominant
negative phenotypes of selected K-Rev mutants, 293T cells were
transfected with 25 ng of pDM128/K-RRE, 25 ng of pBC12/CMV/
-gal, 50 ng of pBC12/CMV/K-Rev (wild type) or pBC12/CMV, and 1,000 ng of
pBC12/CMV or pBC12/CMV/K-Rev encoding wild-type or mutant K-Rev. In a
parallel experiment, the ability of K-Rev mutants to inhibit H-Rev
function was assessed by cotransfection into 293T cells together with
25 ng of pDM128/CMV and 50 ng of pcRev. At ~48 h after transfection,
cells were harvested and lysed, and induced chloramphenicol
acetyltransferase (CAT) and
-galactosidase (
-Gal) activities
determined as previously described (3). In all experiments,
the observed CAT enzyme activities were adjusted for minor differences
in transfection efficiency or sample recovery, using the
-Gal enzyme
activity as an internal control.
Two-hybrid assays in human 293T cells were performed essentially as
previously described (
3,
43). To assay for K-Rev
multimerization, 293T cells were transfected with 250 ng of the
pG6(

31)HIVLTR

TARCAT reporter plasmid, 100 ng of the internal
control plasmid pBC12/CMV/

-gal, 500 ng of pSG424/K-Rev, and 2,000
ng
of pBC12/CMV/K-Rev/VP16 (wild type or mutant) or pBC12/CMV
as a
negative control. Similarly, to measure binding of K-Rev
to Crm1 by
mammalian two-hybrid assay, 293T cells were transfected
with 50 ng of
the pG6(

31)HIVLTR

TARCAT reporter, 250 ng of the
pBC12/CMV/

-gal
internal control, 500 ng of pSG424/CRM1, and 2,000
ng of
pBC12/CMV/K-Rev/VP16 (wild type or mutant) or pBC12/CMV.
In each case,
induced CAT and

-Gal activities were assayed at
~48 h as
previously described (
3).
Immunofluorescence and Western blot assays.
The subcellular
localization of K-Rev mutants in transfected 293T cells, in the
presence or absence of the
CAN protein, was assayed as previously
described (43). Briefly, 293T cells were transfected with
500 ng of pBC12/CMV/K-Rev (wild type or mutant) together with 1 µg of
pBC12/CMV or pBC12/CMV/
CAN. At ~50 h after transfection, cells
were fixed and stained with a 1:500 dilution of a rabbit polyclonal
anti-K-Rev antiserum followed by a 1:2,000 dilution of a fluorescein
isothiocyanate-conjugated donkey anti-rabbit antiserum (The Jackson
Laboratory). Images were collected using a Leica DMRB fluorescence
microscope and converted to grayscale using Adobe Photoshop 4.0 software.
To determine the steady-state expression level of selected VP16/K-Rev
fusion proteins, Western blot assays were performed
essentially as
previously described (
2). Briefly, 293T cells
(35-mm-diameter cultures) were transfected with 1 µg of the relevant
VP16/K-Rev expression plasmid, and cell lysates were prepared
at ~48
h after transfection. After separation by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, proteins were transferred
to nitrocellulose membranes and then probed with the anti-VP16
mouse
monoclonal antibody SC-7545 (Santa Cruz Biotechnology) followed
by a
horseradish peroxidase-conjugated sheep anti-mouse antiserum
(Amersham). Bound antibodies were visualized by enhanced
chemiluminescence
and
autoradiography.
Yeast two- and three-hybrid assays.
To assay for
multimerization of K-Rev, Saccharomyces cerevisiae strain
Y190 cells (19) were transformed with pGBT9/K-Rev together
with pPGK/VP16/K-Rev (wild type or mutant) or pPGK/VP16 as a negative
control. After selection on Leu
Trp
plates
for 3 days, double transformants were harvested and grown overnight in
Leu
Trp
medium. Similarly, for analysis of
RNA binding by K-Rev, yeast strain L40 coat cells (Invitrogen) were
transformed with an RNA expression plasmid (pMS2/K-RRE/s or
pMS2/K-RRE/as as a negative control) and pPGK/VP16/K-Rev (wild type or
mutant). After selection on Ura
Leu
plates
for 3 days, double transformants were harvested and grown overnight in
Ura
Leu
medium. In each case, cell
equivalents were then lysed and assayed for
-Gal activity as
previously described (5).
 |
RESULTS |
A set of 14 missense mutants in the context of the previously
described K-Rev cDNA expression plasmid pBC12/CMV/K-Rev was constructed. In each case, the introduced mutation modified eight nucleotides to the sequence 5'-GCG · GCC · GC-3' (with
the reading frame indicated). This sequence encodes triple alanine, so
that these mutations each introduced alanines in place of the boxed K-Rev residues shown in Fig. 1. These mutations were largely random in
design, although K2 and K3 were targeted to an arginine-rich sequence
that bears some similarity to the arginine-rich RNA binding domain and
NLS seen in both H-Rev and Rex (16, 28, 33, 40). In
addition, K7, K8, and K9 all affect a motif
(50-WAQLKKLTQL-59) that has
been suggested to be similar to the leucine-rich NES present in H-Rev
(27).
Figure 2 shows the ability of each K-Rev
mutant to induce the nuclear export and expression of the unspliced
cat mRNA encoded by the previously described indicator
construct pDM128/K-RRE (43), which also contains the
full-length K-RRE in cis. These data, which are normalized
to values for the wild-type K-Rev expression plasmid, reveal that
mutants K1 and K14 are fully active whereas K3 is almost wild type in
activity. While K9 and possibly K13 displayed weak partial activity,
all of the nine other K-Rev mutants were inactive.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 2.
Biological activities of K-Rev mutants. 293T cells were
cotransfected with the pDM128/K-RRE indicator construct and expression
plasmids encoding wild-type (WT) or mutant K-Rev. The parental
pBC12/CMV expression plasmid served as a negative control (Neg).
Induced CAT activities were assayed at ~48 h after transfection as
previously described (3). These data are normalized to the
activity of wild-type K-Rev, which is arbitrarily set at 100. Results
were also adjusted for nonspecific variability using the -Gal
internal control. Data shown represent the average of three independent
experiments with standard deviation indicated.
|
|
Subcellular localization of K-Rev mutants.
Although K-Rev is
normally largely cytoplasmic when expressed in human cells, inhibition
of Crm1 function either by overexpression of
CAN, a dominant
negative form of the nucleoporin Nup214/CAN that acts as a specific
inhibitor of Crm1 function (3, 12, 24), or by addition of
leptomycin B, a specific Crm1 inhibitor (11), results in the
nuclear accumulation of K-Rev (27, 43). Therefore, we
reasoned that K-Rev mutants that had lost the ability to bind to Crm1
should differ from wild-type K-Rev in being constitutively nuclear.
Further, the localization of each defective mutant by immunofluorescence would also confirm that these proteins are indeed expressed.
Figure
3A exemplifies the normal
subcellular localizations of all 14 K-Rev mutants in human 293T cells.
As may be readily
observed, four of these mutants, K3, K7, K12, and
K13, are nuclear,
while the other 10 mutants share the cytoplasmic
localization
characteristic of wild-type K-Rev. The K12 mutant tended
to concentrate
in nucleoli, as previously also observed for wild-type
K-Rev in
cells lacking functional Crm1 (
27,
43). In
contrast, K3, K7,
and, particularly, K13 were all excluded from the
nucleoli (Fig.
3). Although K3 is nuclear at steady state, it is
nevertheless
active in inducing K-RRE-dependent RNA export (Fig.
2).
Therefore,
K3 must be able to exit the nucleus. As the K3 mutation is
adjacent
to the arginine motif of K-Rev, which, by analogy to H-Rev and
Rex (
33,
40), could function as an NLS, it appears possible
that the K3 mutation may actually enhance the nuclear import of
K-Rev
rather than inhibit its export.

View larger version (93K):
[in this window]
[in a new window]
|
FIG. 3.
Subcellular localization of K-Rev. The subcellular
localization of K-Rev in transfected 293T cells, in the absence (A) or
presence (B) of the CAN inhibitor of Crm1 function, was determined
as previously described (43), using a rabbit polyclonal
anti-K-Rev antiserum. WT, wild type.
|
|
While the nuclear export of K-Rev is dependent on Crm1 (
27,
43), the mechanism mediating K-Rev nuclear import is not known.
However, if a K-Rev mutant that is normally cytoplasmic (Fig.
3) can
relocalize to the nucleus in the absence of Crm1 function,
then this
would imply that it retains a functional NLS. Conversely,
the continued
cytoplasmic localization of a K-Rev mutant, in the
absence of Crm1
function, would imply that the introduced mutation
had inhibited K-Rev
nuclear import. We therefore examined the
subcellular localization of
normally cytoplasmic K-Rev mutants
in the presence of the Crm1
inhibitor

CAN (Fig.
3B). As may be
seen, mutants K2 and K5 (as well
as mutants K4 and K11 [data not
shown]) fail to accumulate in the
nucleus in the presence of

CAN.
Conversely, mutants K1, K8, and K9
(as well as K6, K10, and K14
[data not shown]) are similar to
wild-type K-Rev (
43) in that

CAN induces their
relocalization from the cytoplasm to the nucleus.
These data therefore
suggest that mutations K2, K4, K5, and K11
all block the effective
nuclear import of K-Rev. While this result
was expected for K2, which
has lost three arginine residues from
the K-Rev basic motif (Fig.
1),
it is unexpected in the case of
the other three K-Rev
mutants.
Crm1 binding by K-Rev mutants.
We have previously reported
that K-Rev can interact specifically with the Crm1 nuclear export
factor both in a mammalian two-hybrid assay and in vitro, in the latter
case only in the presence of Ran · GTP (43). Figure
4A demonstrates the abilities of the K-Rev mutants to interact with Crm1 in vivo. In this assay, 293T cells
were transfected with the indicator construct
pG6(
31)HIVLTR
TARCAT, which contains six GAL4 DNA binding sites
flanking a minimal HIV-1 promoter element linked to the cat
indicator gene (37). These same cells were also transfected
with a plasmid expressing Crm1 fused to the GAL4 DNA binding domain and
a third plasmid expressing the VP16 transcription activation domain
fused to wild-type or mutant K-Rev. The parental pBC12/CMV plasmid
served as a negative control. Binding of K-Rev to Crm1 would result in
recruitment of the VP16 activation domain to the indicator construct
and, hence, activation of CAT expression.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 4.
Crm1 binding by K-Rev mutants. (A) Abilities of K-Rev
mutants to bind to the Crm1 nuclear export factor were determined by
two-hybrid assay in transfected 293T cells, as described previously
(3) and in the text. These data were adjusted using the
-Gal internal control and then expressed as a multiple of the level
of CAT enzyme activity seen in 293T cells transfected with the
indicator construct, the GAL4-Crm1 fusion protein expression plasmid,
and the negative (Neg) control plasmid pBC12/CMV. These are
representative data reflective of four independent transfection
experiments. (B) Western analysis of K-Rev/VP16 fusion protein
expression levels in transfected 293T cells. Blots were probed with a
mouse monoclonal antibody directed against the VP16 activation domain.
Sizes are indicated in kilodaltons.
|
|
These data demonstrate that mutants K1, K4, K5, K6, and K10 are
essentially identical to wild-type K-Rev in the ability to
interact
with Crm1, while K2, K3, K9, K11, K12, K13, and K14 all
appear to be
~2-fold less active. Finally, mutant K7 does not
detectably interact
with Crm1, while K8 is at most slightly active.
While the inability of
mutant K7 to bind to Crm1 is clearly consistent
with the nuclear
localization of K7 observed by immunofluorescence
(Fig.
3), K8 proved
fully able to shuttle between nucleus and
cytoplasm (Fig.
3) despite
its apparently very weak interaction
with Crm1. Conversely, K12 and
K13, which also localize to the
nucleus when Crm1 is functional (Fig.
3), nevertheless bind to
Crm1 as effectively as mutants that clearly do
retain the ability
to shuttle (Fig.
4A).
To confirm that these VP16/K-Rev fusion proteins are indeed expressed
at equivalent levels in vivo, we also performed a Western
blot analysis
on transfected 293T cells. As shown in Fig.
4B,
all tested VP16 fusion
proteins were readily detectable in cellular
extracts, although K4
appears to be slightly overexpressed, and
K7 slightly underexpressed,
compared to their
peers.
Multimerization of K-Rev in vivo.
The ability of H-Rev and
HTLV-1 Rex to multimerize is required for the nuclear export of their
target viral RNA molecules (6, 18, 28, 44). Previously, we
have shown by two-hybrid assay in human 293T cells that K-Rev also has
the ability to multimerize (43), although it has not been
demonstrated formally that this multimerization extends beyond dimer
formation. To address this issue for the K-Rev mutants listed in Fig.
1, we used two-hybrid analysis in yeast cells (9) (Fig.
5A) or in human cells (Fig. 5B) to
measure, in each case, the ability of a fusion protein consisting of
the GAL4 DNA binding domain linked to wild-type K-Rev to bind to
wild-type or mutant K-Rev fused to the VP16 activation domain and to an
active NLS. Gratifyingly, these two assays yielded very similar data
(Fig. 5). Specifically, K7, K11, and K12 were all profoundly defective
for multimerization, while all other K-Rev mutants were comparable in
multimerization activity to wild-type K-Rev.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 5.
Multimerization of the K-Rev protein. (A)
Multimerization of K-Rev was detected in yeast cells using the
two-hybrid assay (9). Cells were transformed with expression
plasmids encoding (i) the GAL4 DNA binding domain fused to wild-type
(WT) K-Rev and (ii) wild-type or mutant K-Rev fused to the VP16
transcription activation domain. Induced -Gal activities were
measured as previously described (5) and are given in
milli-optical density units (mOD) per milliliter of yeast culture. Data
are representative of three independent experiments. (B) Similar to
panel A except that the two-hybrid assay was performed in transfected
human 293T cells, as described in the text. Induced CAT enzyme
activities were measured ~48 h after transfection, adjusted using the
-Gal internal control plasmid, and then normalized to the activity
seen with wild-type K-Rev, which was arbitrarily set at 100. Data are
representative of three independent experiments.
|
|
K-RRE binding by K-Rev.
Previously, we demonstrated that K-Rev
can bind specifically to the K-RRE in vitro but not to irrelevant RNA
targets, such as the H-RRE (43). Elsewhere, we have recently
also documented that K-Rev can specifically bind to the K-RRE, but not
to the antisense K-RRE or to irrelevant RNA targets, in the yeast
three-hybrid assay (36, 42a). We used this three-hybrid
assay to examine the ability of K-Rev mutants to bind the K-RRE (Fig.
6). In this in vivo assay, the sense or
antisense K-RRE was expressed in yeast L40 coat cells as a fusion to
the MS2 bacteriophage operator RNA, while wild-type or mutant K-Rev was
expressed fused to the VP16 activation domain, as in Fig. 5A. As may be
observed in Fig. 6, wild-type K-Rev bound the sense orientation K-RRE
effectively but interacted only very poorly with the antisense K-RRE.
Only one mutant, K2, was entirely negative for K-RRE binding, although K3, K4, K7, K11, and K12 were all clearly less active than wild-type K-Rev. K7, K11, and K12 are defective for multimerization (Fig. 5); it
is therefore possible that their lower K-RRE binding activity reflects
an inability to multimerize effectively on the K-RRE rather than a
reduced affinity for the putative primary K-Rev RNA binding site on the
K-RRE.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 6.
Binding of K-Rev to the K-RRE. Abilities of K-Rev
mutants to bind to the K-RRE in vivo were determined by three-hybrid
assay in yeast (36). L40 coat cells were transformed with an
expression plasmid encoding the full-length sense or antisense K-RRE
fused to the MS2 operator RNA and with a second plasmid expressing a
fusion protein consisting of the VP16 activation domain linked to
wild-type (WT) or mutant K-Rev, as also described for Fig. 5A. The
negative control (Neg) consists of yeast cells expressing the
MS2/K-RRE/as (antisense) RNA and the wild-type VP16/K-Rev fusion
protein. Induced -Gal activities were determined as previously
described (5).
|
|
Inactive K-Rev mutants exert a dominant negative phenotype.
The mutational analysis presented in this report identified nine K-Rev
mutants that have lost the ability to mediate the nuclear export of
unspliced mRNAs bearing the K-RRE. Previously, it has been demonstrated
that certain inactive mutants of H-Rev or HTLV-1 Rex can exert a potent
dominant negative phenotype when coexpressed with the wild-type form of
the same protein, particularly if expressed in excess (7, 30,
35). To test whether this phenotype would also be detected for
any of the nine inactive K-Rev mutants identified in this study, we
transfected 293T cells with the pDM128/K-RRE indicator construct and 50 ng of the wild-type K-Rev expression plasmid pBC12/CMV/K-Rev together
with 1,000 ng of pBC12/CMV/K-Rev expressing either wild-type or
defective mutant K-Rev. As shown in Fig.
7A, each of the nine inactive K-Rev
mutants, but not wild-type K-Rev, proved able to potently inhibit the
expression of the unspliced cat mRNA containing the K-RRE
when expressed at ~20-fold excess over the wild-type protein. This
inhibition was specific, as none of these K-Rev mutants had any
significant effect on the level of expression of the
-Gal enzyme
encoded by the cotransfected pBC12/CMV/
-gal internal control plasmid
(data not shown).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 7.
Dominant negative phenotypes of K-Rev mutants. (A) 293T
cells were transfected with 25 ng of the indicator construct
pDM128/K-RRE, 50 ng of pBC12/CMV (Neg), or 50 ng of the wild-type (WT)
K-Rev expression plasmid pBC12/CMV/K-Rev. In addition, the cells were
cotransfected with 1 µg of the parental pBC12/CMV plasmid (Neg and
Control) or with 1 µg of a pBC12/CMV-based plasmid encoding wild-type
or mutant K-Rev. Induced CAT activities were determined at ~48 h
posttransfection, adjusted using the -Gal internal standard, and
then normalized to the control activity, which was arbitrarily set at
100. These data represent the average of three independent experiments
with the standard deviation indicated. (B) Similar to panel A except
that 293T cells were transfected with 25 ng of the H-RRE-based
indicator plasmid pDM128/CMV and with 50 ng of the H-Rev expression
plasmid pcRev. M32 is a previously described (30) dominant
negative mutant of H-Rev.
|
|
To further confirm the specificity of this inhibition, we transfected
293T cells as described for Fig.
7A except that pDM128/K-RRE
was
replaced by the similar indicator plasmid pDM128/CMV, which
contains
the H-RRE in place of the K-RRE (
30), while pBC12/CMV/K-Rev
was substituted with an expression plasmid, pcRev, encoding wild-type
H-Rev. As shown in Fig.
7B, coexpression of H-Rev activated expression
of the
cat gene encoded by the pDM128/CMV indicator plasmid;
this
has previously been shown to result from the H-Rev-induced nuclear
export of the encoded unspliced
cat mRNA (
23,
30). As a control,
we cotransfected a previously described
(
30) dominant negative
mutant of H-Rev, termed M32, that
lacks a functional NES. As expected,
this resulted in >20-fold
inhibition of CAT expression (Fig.
7B).
In contrast, the K-Rev mutants
that potently inhibited wild-type
K-Rev function (Fig.
7A) had no
significant inhibitory effect
on H-Rev (Fig.
7B); the inhibition of the
K-Rev-induced
cat mRNA
expression reported in Fig.
7A
therefore clearly reflects a specific,
dominant negative
phenotype.
 |
DISCUSSION |
The critical importance of H-Rev in the HIV-1 replication cycle
and the fact that H-Rev was the first sequence-specific nuclear mRNA
export factor to be identified have led to considerable interest in the
mechanism of action of H-Rev (8, 34). As a result, H-Rev has
been subjected to intense mutational analysis, which has led to the
fairly precise definition of the sequences within H-Rev required for
RNA binding, nuclear localization, homomultimerization, and Crm1
binding. Mutation of the leucine-rich Crm1 binding motif on H-Rev,
which also blocks Rev nuclear export, gives rise to a potent dominant
negative phenotype (10, 11, 30, 31). This inhibition most
probably reflects the formation of inactive multimers, containing both
mutant and wild-type H-Rev, on the K-RRE. On the other hand, H-Rev
mutants that are unable to bind the K-RRE or to multimerize are
essentially recessive negative (28, 30). Importantly,
mutations that block H-Rev function can be shown to inactivate one or
more of the biological properties of H-Rev enumerated above (28,
30, 34).
Although the HTLV-1 Rev protein has not yet been subjected to the level
of experimental analysis applied to H-Rev, Rex has been shown to share
a similar set of functional domains, albeit not in the same relative
position within the linear protein sequence (6, 18, 22, 33,
41). Again, mutations that block Rex function have been shown to
affect RNA binding, Crm1 binding, multimerization, or NLS function. Of
interest, while certain Rex mutants are also dominant negative, these
appear to be defective for multimerization rather than for Crm1
recruitment, and they have therefore been proposed to act by a
squelching mechanism (20).
Previously, we had demonstrated that K-Rev, like H-Rev and Rex, is able
to bind to Crm1 and to its cognate RNA target, the K-RRE, as well as to
multimerize and to shuttle between nucleus and cytoplasm
(43). We therefore sought to use mutational analysis to
identify the functional domains important for these biological activities and to assess their role in K-Rev-mediated nuclear RNA
export. It was anticipated that these experiments would permit a
comparison of the functional architecture of K-Rev with that of H-Rev
and Rex and hence perhaps shed new light on the evolution of these
unusual retroviral regulatory proteins.
This report described 14 missense mutants of the 105-aa K-Rev protein
and reports an extensive analysis of the biological properties of these
mutants, 9 of which have lost the ability to induce K-RRE-dependent RNA
export activity (summarized in Table 1). Importantly, all of these
K-Rev mutants were expressed at readily detectable levels, as
determined by immunofluorescence (Fig. 3) or Western blot analysis
(Fig. 4B). Further, all K-Rev mutants retained one or more specific
biological functions (Table 1), and
therefore are not acting by simply inducing a global misfolding of the
K-Rev protein.
RNA binding and nuclear import.
The RNA binding and NLS
sequences in H-Rev and Rex both coincide with an arginine-rich motif
(16, 28, 33, 40); we therefore anticipated that the similar
arginine-rich sequence present in K-Rev (Fig. 1) might fulfill a
similar function. Of the 14 mutations introduced into K-Rev, 2 (K2 and
K3) were targeted to this basic motif. The K2 mutant was found to be
inactive, while K3 retained almost full activity (Fig. 2), thus
implying that the latter mutation was not particularly deleterious.
Analysis of K-RRE binding by the K-Rev mutants showed that K2 lacked
any binding ability whereas the ability of K3 was significantly
attenuated (Fig.
6). Therefore, it appears that the K-Rev arginine
motif is indeed critical for binding to the K-RRE. All other K-Rev
mutants except K7, K11, and K12 bound the K-RRE effectively. However,
these three exceptions are all defective for multimerization (Fig.
5),
and we believe their lower K-RRE binding activity likely reflects
their
inability to effectively multimerize on the K-RRE.
While the wild-type K-Rev protein is normally cytoplasmic, specific
inactivation of Crm1 function results in localization
of K-Rev to the
nucleus (
27,
43). This result demonstrates
that K-Rev is a
nucleocytoplasmic shuttle protein whose cytoplasmic
localization
requires ongoing nuclear export mediated by Crm1
and implies the
existence of an NLS whose function is revealed
only when K-Rev nuclear
export is inhibited. However, a fusion
protein consisting of the
amino-terminal 29 aa of K-Rev, including
the entire basic domain,
linked to the heterologous

-Gal protein
only weakly localized to the
nucleus (H. Wiegand, unpublished
observation), thus implying that the
K-Rev NLS is not active in
this fusion protein context or that this NLS
extends significantly
beyond the K-Rev arginine motif (Fig.
1). We
therefore instead
attempted to define the putative K-Rev NLS by
subcellular localization
of mutants of full-length K-Rev using
immunofluorescence analysis
(Fig.
3).
The phenotype expected for a K-Rev protein lacking a functional NLS is
continued cytoplasmic localization even in the absence
of Crm1
function. This is in fact exactly what is seen with K2
(Fig.
3), thus
supporting the hypothesis that the K-Rev arginine
motif is important
for K-Rev nuclear import. Surprisingly, however,
mutants K4, K5, and
K11 were also all cytoplasmic when Crm1 was
inhibited. Therefore, these
mutants appear to have lost the ability
to import into the nucleus.
This finding suggests the surprising
possibility that nuclear import of
K-Rev is mediated by the combined
action of several discontinuous K-Rev
sequences. If true, this
result would clearly explain why fusion of
only the amino-terminal
29 aa of K-Rev to

-Gal did not result in
effective nuclear import
(see
above).
Analysis of the subcellular localization of K-Rev mutants (Fig.
3)
revealed that K3 was nuclear at steady state. Because K3
is, however,
biologically active (Fig.
2), it seems improbable
that this reflects an
inability to export from the nucleus. We
therefore hypothesize that the
K3 mutation may actually enhance
the function of the otherwise
relatively ineffective NLS present
in K-Rev, so that import becomes
more efficient than Crm1-dependent
export, i.e., the situation normally
seen with H-Rev and Rex (
33,
40). However, this hypothesis
can be substantiated only by a
more complete analysis of K-Rev
nucleocytoplasmic
transport.
Crm1 binding and nuclear export.
Analysis of Crm1 binding to
K-Rev in 293T cells (Fig. 4A) showed that K7 was defective for Crm1
binding whereas the activity of K8 was highly attenuated. K9 and K12
were also somewhat attenuated for Crm1 binding, while all other mutants
showed
50% of the wild-type K-Rev activity. The K7 mutant was found
to be nuclear at steady state (Fig. 3), consistent with a block in
Crm1-dependent nuclear export. Surprisingly, K8 retained cytoplasmic
localization in the presence of functional Crm1 and became nuclear in
the absence of Crm1 function (Fig. 3), thus implying that the weak
interaction observed between K8 and Crm1 (Fig. 4A) was sufficient to
maintain nucleocytoplasmic shuttling. Not only K7 but also K3, K12, and K13 were nuclear at steady state. Of interest, K13 was specifically excluded from nucleoli whereas K12 tended to concentrate in the nucleoli (Fig. 3), as also seen for wild-type K-Rev in the absence of
Crm1 function (27, 43). The significance of this difference is not, however, clear. We have argued above that the active K3 mutant
is likely nuclear due to enhanced NLS function. Both K12 and K13 retain
substantial Crm1 binding activity, and it is therefore possible that
they also exhibit enhanced nuclear import. Alternately, they may be
retained in the nucleus for unknown reasons distinct from any inability
to recruit Crm1.
H-Rev and Rex, as well as most other proteins that depend on Crm1 to
mediate their nuclear export, have been shown to contain
a short,
leucine-rich sequence that serves as a specific Crm1
binding site and
hence as an NES (
3,
4,
10,
11,
25,
31,
38,
42). The function
of this NES is dependent on the
appropriate spacing of four
hydrophobic, most commonly leucine,
residues interspersed by smaller,
hydrophilic residues. A consensus
sequence for leucine-rich NESs that
envisages a spacing of two
or three residues between leucines 1 and 2 and leucines 2 and
3 and a single residue between leucine residues 3 and 4 has been
proposed (
4,
25). This latter spacing appears
invariant in
functional leucine-rich NESs (
25). While the
K-Rev sequence
50-
WAQ
LKK
LTQ
L-59 bears some
similarity
to known leucine-rich NESs (
8,
27,
34), it
clearly does
not have a single-residue spacer between the two most
carboxy-terminal
leucines and therefore does not conform to this
consensus. Nevertheless,
mutation K7, which changes tryptophan 50 to
alanine, blocks Crm1
binding, while mutations K8, which changes leucine
53 to alanine,
and K9, which changes leucine 59 to alanine, reduce Crm1
binding
(Fig.
4A). However, the latter two mutants differ from K7 in
that
they retain the ability to shuttle between nucleus and cytoplasm
(Fig.
3). Although this K-Rev motif could represent an unusual
leucine-rich NES, substitution of this sequence for the authentic
leucine-rich NES present in H-Rev did not rescue H-Rev function
(Bogerd, unpublished), even though leucine-rich NESs from several
proteins have previously been shown to support H-Rev-induced nuclear
export when switched for the H-Rev NES (
13-15,
22,
41). To
test whether repair of the spacing of the leucine residues in
the
putative K-Rev NES would enhance activity, we exchanged the
last two
residues to give
50-
WAQ
LKK
LT
LQ-59,
a
sequence that closely matches the NES consensus (
4,
25).
However, this did not result in enhanced K-Rev function (Bogerd,
unpublished).
K-Rev multimerization.
The ability of K-Rev to multimerize or,
more accurately, to at least dimerize was assayed in both human and
yeast cells (Fig. 5). In both systems, K7, K11, and K12 were defective
for multimerization whereas all other mutants were essentially wild
type. It has previously been demonstrated that Crm1 substantially
enhances both H-Rev and Rex multimerization in vivo (6, 18,
26), and these latter two proteins, at least, are known to bind
to Crm1 in not only human but also yeast cells (31). It
therefore seems possible that the inability of the K7 mutant to bind to
Crm1 (Fig. 4A) may underly the apparent defect in multimerization. If
this is the case, then the true multimerization domain in K-Rev would actually coincide with the sequence defined by mutants K11 and K12,
both of which lack K-RRE nuclear export activity.
Biological activities of K-Rev mutants.
The data discussed
above suggest that RNA binding by K-Rev involves an obvious
arginine-rich motif (residues 8 to 20) that bears a clear similarity to
the arginine-rich RNA binding domains present in H-Rev and Rex (8,
16, 28, 34). This motif also appears important for nuclear import
of K-Rev. Binding to Crm1 requires the integrity of a K-Rev sequence
(residues 50 to 59) that features several large hydrophobic residues,
although this motif appears distinct from the NESs previously defined
in H-Rev and Rex (4, 8, 25, 34). Finally, K-Rev
multimerization appears to require residues localized around 76 to 84.
Unfortunately, these data do not allow us to fully explain the RNA
export activities observed for some K-Rev mutants. Particularly
puzzling is why certain K-Rev mutants are unable to support
K-RRE-dependent
nuclear export when they appear wild type for all
properties examined.
Specifically, mutants K6, K8, and K10 appear fully
active for
RNA binding, Crm1 binding, multimerization, and
nucleocytoplasmic
shuttling yet are inactive for RNA export (Fig.
2;
Table
1).
No equivalent mutants have so far been described for H-Rev or
Rex. A further mystery is that all nine inactive K-Rev mutants
turn out
to be potent dominant negative inhibitors of K-Rev (Fig.
7). This is
clearly unlike the situation reported for H-Rev and
Rex, where dominant
negative mutants selectively block Crm1 binding
and multimerization,
respectively (
6,
11,
18,
28,
30,
31,
38). In contrast, these
nine K-Rev mutants are defective
in several different ways (Table
1).
However, it is unlikely
that these K-Rev mutants act by sequestering a
limiting supply
of Crm1, both because K7, which does not bind to Crm1,
is a dominant
negative mutant (Fig.
4A and
7A) and because none of
these K-Rev
mutants proved able to inhibit H-Rev function (Fig.
7B).
In conclusion, we have defined sequences in K-Rev that function in Crm1
and K-RRE binding, multimerization, and K-Rev nucleocytoplasmic
shuttling. While each of these activities appears critical for
K-Rev
function, their loss does not fully suffice to explain the
phenotypes
observed for certain K-Rev mutants in mediating K-RRE-dependent
nuclear
RNA export. Our data may therefore imply the existence
of an
additional, unknown interaction that is required to mediate
K-Rev
function but that may play no role in the nuclear mRNA export
induced
by the perhaps more highly evolved H-Rev and HTLV-1 Rex
proteins.
 |
ACKNOWLEDGMENT |
The first two authors contributed equally to this report.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: HHMI and
Department of Genetics, Box 3025, Duke University Medical Center,
Durham, NC 27710. Phone: (919) 684-3369. Fax: (919) 681-8979. E-mail: culle002{at}mc.duke.edu.
 |
REFERENCES |
| 1.
|
Barbulescu, M.,
G. Turner,
M. I. Seaman,
A. S. Deinard,
K. K. Kidd, and J. Lenz.
1999.
Many human endogenous retrovirus K (HERV-K) proviruses are unique to humans.
Curr. Biol.
9:861-868[CrossRef][Medline].
|
| 2.
|
Bieniasz, P. D.,
T. A. Grdina,
H. P. Bogerd, and B. R. Cullen.
1998.
Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.
EMBO J.
17:7056-7065[CrossRef][Medline].
|
| 3.
|
Bogerd, H. P.,
A. Echarri,
T. M. Ross, and B. R. Cullen.
1998.
Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1.
J. Virol.
72:8627-8635[Abstract/Free Full Text].
|
| 4.
|
Bogerd, H. P.,
R. A. Fridell,
R. E. Benson,
J. Hua, and B. R. Cullen.
1996.
Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay.
Mol. Cell. Biol.
16:4207-4214[Abstract].
|
| 5.
|
Bogerd, H. P.,
R. A. Fridell,
W. S. Blair, and B. R. Cullen.
1993.
Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus.
J. Virol.
67:5030-5034[Abstract/Free Full Text].
|
| 6.
|
Bogerd, H., and W. C. Greene.
1993.
Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo.
J. Virol.
67:2496-2502[Abstract/Free Full Text].
|
| 7.
|
Böhnlein, S.,
F. P. Pirker,
L. Hofer,
K. Zimmermann,
H. Bachmayer,
E. Böhnlein, and J. Hauber.
1991.
Transdominant repressors for human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev function.
J. Virol.
65:81-88[Abstract/Free Full Text].
|
| 8.
|
Cullen, B. R.
1998.
Retroviruses as model systems for the study of nuclear RNA export pathways.
Virology
249:203-210[CrossRef][Medline].
|
| 9.
|
Fields, S., and O.-K. Song.
1989.
A novel genetic system to detect protein-protein interactions.
Nature
340:245-246[CrossRef][Medline].
|
| 10.
|
Fischer, U.,
J. Huber,
W. C. Boelens,
I. W. Mattaj, and R. Lührmann.
1995.
The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs.
Cell
82:475-483[CrossRef][Medline].
|
| 11.
|
Fornerod, M.,
M. Ohno,
M. Yoshida, and I. W. Mattaj.
1997.
CRM1 is an export receptor for leucine-rich nuclear export signals.
Cell
90:1051-1060[CrossRef][Medline].
|
| 12.
|
Fornerod, M.,
J. van Deursen,
S. Van Baal,
A. Reynolds,
D. Davis,
K. G. Murti,
J. Fransen, and G. Grosveld.
1997.
The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88.
EMBO J.
16:807-816[CrossRef][Medline].
|
| 13.
|
Fridell, R. A.,
R. E. Benson,
J. Hua,
H. P. Bogerd, and B. R. Cullen.
1996.
A nuclear role for the fragile X mental retardation.
EMBO J.
15:5408-5414[Medline].
|
| 14.
|
Fridell, R. A.,
H. P. Bogerd, and B. R. Cullen.
1996.
Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway.
Proc. Natl. Acad. Sci. USA
93:4421-4424[Abstract/Free Full Text].
|
| 15.
|
Fridell, R. A.,
U. Fischer,
R. Lührmann,
B. E. Meyer,
J. L. Meinkoth,
M. H. Malim, and B. R. Cullen.
1996.
Amphibian transcription factor IIIA proteins contain a sequence element functionally equivalent to the nuclear export signal of human immunodeficiency virus type 1 Rev.
Proc. Natl. Acad. Sci. USA
93:2936-2940[Abstract/Free Full Text].
|
| 16.
|
Grassmann, R.,
S. Berchtold,
C. Aepinus,
C. Ballaun,
E. Boehnlein, and B. Fleckenstein.
1991.
In vitro binding of human T-cell leukemia virus Rex proteins to the Rex-response element of viral transcripts.
J. Virol.
65:3721-3727[Abstract/Free Full Text].
|
| 17.
|
Griffiths, D. J.,
P. J. W. Venables,
R. A. Weiss, and M. T. Boyd.
1997.
A novel exogenous retrovirus sequence identified in humans.
J. Virol.
71:2866-2872[Abstract].
|
| 18.
|
Hakata, Y.,
T. Umemoto,
S. Matsushita, and H. Shida.
1998.
Involvement of human CRM1 (exportin 1) in the export and multimerization of the Rex protein of human T-cell leukemia virus type I.
J. Virol.
72:6602-6607[Abstract/Free Full Text].
|
| 19.
|
Harper, J. W.,
G. R. Adami,
N. Wei,
K. Keyomarsi, and S. J. Elledge.
1993.
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Cell
19:805-816.
|
| 20.
|
Heger, P.,
O. Rosorius,
J. Hauber, and R. H. Stauber.
1999.
Titration of cellular export factors, but not heteromultimerization, is the molecular mechanism of trans-dominant HTLV-I Rex mutants.
Oncogene
18:4080-4090[CrossRef][Medline].
|
| 21.
|
Hidaka, M.,
J. Inoue,
M. Yoshida, and M. Seiki.
1988.
Post-transcriptional regulator (Rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins.
EMBO J.
7:519-523[Medline].
|
| 22.
|
Hope, T. J.,
B. L. Bond,
D. McDonald,
N. P. Klein, and T. G. Parslow.
1991.
Effector domains of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex are functionally interchangeable and share an essential peptide motif.
J. Virol.
65:6001-6007[Abstract/Free Full Text].
|
| 23.
|
Hope, T. J.,
X. Huang,
D. McDonald, and T. G. Parslow.
1990.
Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif.
Proc. Natl. Acad. Sci. USA
87:7787-7791[Abstract/Free Full Text].
|
| 24.
|
Kang, Y., and B. R. Cullen.
1999.
The human Tap protein is a nuclear mRNA export factor that contains novel RNA-binding and nucleocytoplasmic transport sequences.
Genes Dev.
13:1126-1139[Abstract/Free Full Text].
|
| 25.
|
Kim, F. J.,
A. A. Beeche,
J. J. Hunter,
D. J. Chin, and T. J. Hope.
1996.
Characterization of the nuclear export signal of human T-cell lymphotropic virus type 1 Rex reveals that nuclear export is mediated by position-variable hydrophobic interactions.
Mol. Cell. Biol.
16:5147-5155[Abstract].
|
| 26.
|
Madore, S. J.,
L. S. Tiley,
M. H. Malim, and B. R. Cullen.
1994.
Sequence requirements for Rev multimerization in vivo.
Virology
202:186-194[CrossRef][Medline].
|
| 27.
|
Magin, C.,
R. Löwer, and J. Löwer.
1999.
cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K.
J. Virol.
73:9496-9507[Abstract/Free Full Text].
|
| 28.
|
Malim, M. H., and B. R. Cullen.
1991.
HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency.
Cell
65:241-248[CrossRef][Medline].
|
| 29.
|
Malim, M. H.,
J. Hauber,
S.-Y. Le,
J. V. Maizel, and B. R. Cullen.
1989.
The HIV-1 Rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.
Nature
338:254-257[CrossRef][Medline].
|
| 30.
|
Malim, M. H.,
D. F. McCarn,
L. S. Tiley, and B. R. Cullen.
1991.
Mutational definition of the human immunodeficiency virus type 1 Rev activation domain.
J. Virol.
65:4248-4254[Abstract/Free Full Text].
|
| 31.
|
Neville, M.,
F. Stutz,
L. Lee,
L. I. Davis, and M. Rosbash.
1997.
The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export.
Curr. Biol.
7:767-775[CrossRef][Medline].
|
| 32.
|
Ohno, M.,
A. Segref,
A. Bachi,
M. Wilm, and I. W. Mattaj.
2000.
PHAX, a mediator of U snRNA nuclear export whose activity is regulated by phosphorylation.
Cell
101:187-198[CrossRef][Medline].
|
| 33.
|
Palmeri, D., and M. H. Malim.
1999.
Importin can mediate the nuclear import of an arginine-rich nuclear localization signal in the absence of importin .
Mol. Cell. Biol.
19:1218-1225[Abstract/Free Full Text].
|
| 34.
|
Pollard, V. W., and M. H. Malim.
1998.
The HIV-1 Rev protein.
Annu. Rev. Microbiol.
52:491-532[CrossRef][Medline].
|
| 35.
|
Rimsky, L.,
M. Duc Dodon,
E. P. Dixon, and W. C. Greene.
1989.
Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator.
Nature
341:453-456[CrossRef][Medline].
|
| 36.
|
SenGupta, D. J.,
B. Zhang,
B. Kraemer,
P. Pochart,
S. Fields, and M. Wickens.
1996.
A three-hybrid system to detect RNA-protein interactions in vivo.
Proc. Natl. Acad. Sci. USA
93:8496-8501[Abstract/Free Full Text].
|
| 37.
|
Southgate, C. D., and M. R. Green.
1991.
The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function.
Genes Dev.
5:2496-2507[Abstract/Free Full Text].
|
| 38.
|
Stade, K.,
C. S. Ford,
C. Guthrie, and K. Weis.
1997.
Exportin 1 (Crm1p) is an essential nuclear export factor.
Cell
90:1041-1050[CrossRef][Medline].
|
| 39.
|
Tristem, M.
2000.
Identification and characterization of novel human endogenous retrovirus families by phylogenetic screening of the human genome mapping project database.
J. Virol.
74:3715-3730[Abstract/Free Full Text].
|
| 40.
|
Truant, R., and B. R. Cullen.
1999.
The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin -dependent nuclear localization signals.
Mol. Cell. Biol.
19:1210-1217[Abstract/Free Full Text].
|
| 41.
|
Weichselbraun, I.,
G. K. Farrington,
J. R. Rusche,
E. Böhnlein, and J. Hauber.
1992.
Definition of the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex protein activation domain by functional exchange.
J. Virol.
66:2583-2587[Abstract/Free Full Text].
|
| 42.
|
Wen, W.,
J. L. Meinkoth,
R. Y. Tsien, and S. S. Taylor.
1995.
Identification of a signal for rapid export of proteins from the nucleus.
Cell
82:463-473[CrossRef][Medline].
|
| 42a.
| Yang, J., H. P. Bogerd, S.-Y. Le, and B. R. Cullen.
The human endogenous retrovirus K Rev response element coincides with a
predicted RNA folding region. RNA, in press.
|
| 43.
|
Yang, J.,
H. P. Bogerd,
S. Peng,
H. Wiegand,
R. Truant, and B. R. Cullen.
1999.
An ancient family of human endogenous retroviruses encodes a functional homolog of the HIV-1 Rev protein.
Proc. Natl. Acad. Sci. USA
96:13404-13408[Abstract/Free Full Text].
|
| 44.
|
Zapp, M. L.,
T. J. Hope,
T. G. Parslow, and M. R. Green.
1991.
Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif.
Proc. Natl. Acad. Sci. USA
88:7734-7738[Abstract/Free Full Text].
|
Journal of Virology, October 2000, p. 9353-9361, Vol. 74, No. 20
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Heslin, D. J., Murcia, P., Arnaud, F., Van Doorslaer, K., Palmarini, M., Lenz, J.
(2009). A Single Amino Acid Substitution in a Segment of the CA Protein within Gag That Has Similarity to Human Immunodeficiency Virus Type 1 Blocks Infectivity of a Human Endogenous Retrovirus K Provirus in the Human Genome. J. Virol.
83: 1105-1114
[Abstract]
[Full Text]
-
Smulevitch, S., Michalowski, D., Zolotukhin, A. S., Schneider, R., Bear, J., Roth, P., Pavlakis, G. N., Felber, B. K.
(2005). Structural and Functional Analysis of the RNA Transport Element, a Member of an Extensive Family Present in the Mouse Genome. J. Virol.
79: 2356-2365
[Abstract]
[Full Text]